Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported Cash and Equivalents of $1.51 million for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.51M | -9.0% |
| 2024 | $1.66M | -22.6% |
| 2023 | $2.14M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.12M | — | +109.2% |
| June 30, 2025 | $1.97M | — | -43.0% |
| March 31, 2025 | $3.45M | — | +108.0% |
| December 31, 2024 | $1.66M | — | — |
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -9.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, 60 DEGREES PHARMACEUTICALS, INC.’s cash and equivalents has declined by 29.5% (from $2.14 million to $1.51 million).
- The most recent figure is from 60 DEGREES PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: